2024
Screening, brief intervention, and referral to treatment for pain management for veterans separating from military service: study protocol of a hybrid type 2 study testing implementation facilitation versus training-as-usual
Sellinger J, Rosen M, Lazar C, Gilstad-Hayden K, Dziura J, Li F, Mattocks K, Weede A, Sullivan-Tibbs M, Rose L, Vassallo G, Manhapra A, Turner A, Vogt D, Woodward E, Hartmann C, Haskell S, Mohammad A, Martino S. Screening, brief intervention, and referral to treatment for pain management for veterans separating from military service: study protocol of a hybrid type 2 study testing implementation facilitation versus training-as-usual. Pain Medicine 2024, 25: s99-s106. PMID: 39514877, DOI: 10.1093/pm/pnae062.Peer-Reviewed Original ResearchConceptsTraining-as-usualImplementation facilitatorsReferral to treatmentCase managementBrief interventionHybrid type 2 effectiveness-implementation trialPain managementImplementation strategiesPrimary implementation outcomeSubstance misuseProportion of participantsPain careUsefulness of screeningVeteran engagementVA sitesImplementation outcomesPragmatic trialPain serviceVeteran participantsCase management systemPain intensityDischarged veteransStudy enrollmentVeteransChronic painPersistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapyTrends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effectsThe impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction
Hazan H, Ferrara M, Riley S, Li F, Zhou B, Kline E, Gibbs-Dean T, Karmani S, Tayfur S, Tek C, Keshavan M, Srihari V. The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction. Schizophrenia Research 2024, 264: 457-461. PMID: 38266513, PMCID: PMC10923115, DOI: 10.1016/j.schres.2024.01.022.Peer-Reviewed Original ResearchConceptsCoordinated specialty careDuration of untreated psychosisImpact of early detectionEarly detectionEarly detection campaignsSpecialty careAdjustment scoresCampaign yearDetection campaignsMediation analysisEffects of EDRegression modelsCareUntreated psychosisPositive symptomsGAFPatientsSalutary effects
2023
The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst yearRandomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseProportion of patientsBreast cancerNeoadjuvant chemotherapyChemotherapy completionComplete responseNutrition interventionsHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerChemotherapy dose adjustmentsHome-based exerciseGrowth factor receptor 2Breast cancer outcomesEffects of exerciseFactor receptor 2Electronic medical recordsChi-square testUsual careDose intensityExercise interventionDose adjustmentRandomized trialsPrior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinationB-cell-depleted patientsB-cell depletionAntibody responseMRNA vaccinationThird doseCell depletionT cellsClaude D. Pepper Older Americans Independence CenterB cellsNational Multiple Sclerosis SocietyAnti-CD20 antibodySpike-specific antibodiesMultiple Sclerosis SocietyLow cumulative exposureLogistic regression modelsImportant clinical needCD20 therapyCD20 treatmentMost patientsThird vaccineSerologic responseVaccine dosesMRNA vaccinesVaccination strategiesEffect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer
Cao A, Cartmel B, Li F, Gottlieb L, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Esserman D, Irwin M, Ferrucci L. Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer. JAMA Network Open 2023, 6: e2326463. PMID: 37526937, PMCID: PMC10394582, DOI: 10.1001/jamanetworkopen.2023.26463.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyAerobic exercise interventionAttention control armExercise intervention armExercise interventionOvarian cancerControl armIntervention armSecondary analysisCIPN symptomsPeripheral neuropathyLifestyle StudyTreatment of CIPNModerate-intensity aerobic exerciseStandard oncology careEffects of exerciseSevere adverse effectsBetween-group differencesAmerican Cancer SocietyQuality of lifeAttention controlCIPN severityPrimary outcomeOncology careAerobic exerciseRandomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Risch H, Irwin M. Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine 2023, 12: 15492-15503. PMID: 37269192, PMCID: PMC10417064, DOI: 10.1002/cam4.6187.Peer-Reviewed Original ResearchConceptsExercise interventionOvarian cancerTrial of exerciseExercise-induced changesMin/weekGroup differencesSubset of participantsCause mortalityExercise groupOverall survivalStudy armsCA 125Randomized trialsBlood biomarkersBlood drawBreast cancerClinical significanceIGF-1Effect model analysisSecondary analysisBeneficial effectsCancerBiomarkersTrialsWomenEffect of a Home Health and Safety Intervention on Emergency Department Use in the Frail Elderly: A Prospective Observational Study
Bogucki S, Siddiqui G, Carter R, McGovern J, Dziura J, Gan G, Li F, Stover G, Cone D, Brokowski C, Joseph D. Effect of a Home Health and Safety Intervention on Emergency Department Use in the Frail Elderly: A Prospective Observational Study. Western Journal Of Emergency Medicine 2023, 0: 522-531. PMID: 37278776, PMCID: PMC10284516, DOI: 10.5811/westjem.58378.Peer-Reviewed Original ResearchConceptsProspective observational studyED utilizationObservational studySubsequent ED utilizationEmergency department useEmergency department utilizationHome health nursesOutcomes of interestHome health programsLimited statistical powerSubsequent EDED evaluationStudy armsGeriatric patientsDepartment useHealth nursesFall riskStudy interventionHome visitsHome healthFrail ElderlyCognitive declineUseful markerHealth programsFrailtySampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis
Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesClinical high riskClinical high-risk individualsEarly detectionFirst-episode psychosis individualsRecent psychiatric hospitalizationCourse of illnessHigh-risk individualsAttenuated positive symptomsCHR researchGeographic catchmentSyndromal psychosisPsychosis individualsPsychiatric hospitalizationEarly intervention effortsHigh riskPsychosis servicesPositive symptomsGlobal functioningClinical resourcesProtective factorsDifferent populationsFE participantsGeneralizability of findingsFES programPercutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies.
Dussik C, Toombs C, Alder K, Yu K, Berson E, Ibe I, Li F, Lindskog D, Friedlaender G, Latich I, Lee F. Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies. Radiology 2023, 307: e221401. PMID: 36916888, DOI: 10.1148/radiol.221401.Peer-Reviewed Original ResearchConceptsOsteolytic neoplasmAmbulatory functionInternal fixationEastern Cooperative Oncology Group scoreIndex scoreConversion hip arthroplastyRetrospective observational studySurgical site infectionKaplan-Meier analysisLong-term painQuality of lifeLong-term improvementWilcoxon signed-rank testNonambulatory patientsSecondary outcomesPrimary outcomeSite infectionOncologic careECOG scorePercutaneous ablationPeriacetabular metastasisProtrusio acetabuliFunctional improvementSigned-rank testClinical dataEfficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacyRacial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems
Holland W, Li F, Nath B, Jeffery M, Stevens M, Melnick E, Dziura J, Khidir H, Skains R, D'Onofrio G, Soares W. Racial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems. Academic Emergency Medicine 2023, 30: 709-720. PMID: 36660800, PMCID: PMC10467357, DOI: 10.1111/acem.14668.Peer-Reviewed Original ResearchConceptsOpioid use disorderCommunity emergency departmentsEmergency departmentDischarge diagnosisHealth care systemHispanic patientsBlack patientsHospital typeCare systemNon-Hispanic patientsOpioid overdose deathsClinical decision support systemOpioid withdrawalPrimary outcomeMedication treatmentBuprenorphine accessED treatmentTreatment accessOverdose deathsX-waiverBuprenorphinePatientsUse disordersEthnic disparitiesSecondary analysis
2022
Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivors
Cao A, Cartmel B, Li F, Gottlieb L, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Irwin M, Ferrucci L. Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivors. Journal Of Cancer Survivorship 2022, 17: 535-543. PMID: 36550261, PMCID: PMC10038915, DOI: 10.1007/s11764-022-01325-6.Peer-Reviewed Original ResearchConceptsOvarian cancer survivorsMin/weekCancer survivorsExercise goalsCancer recurrenceCounseling sessionsSession attendanceExercise adherenceHigher baseline activity levelsWeekly exercise durationTrial of exerciseMean exercise timeVigorous-intensity exerciseBaseline activity levelsQuality of lifeMore counseling sessionsExercise interventionExercise durationWeek exerciseLifestyle StudyExercise timeOvarian cancerNumber of sessionsCounseling intensitySurvivorsDUP redux: Observations vs. experiments in early intervention (invited commentary on Nkire et al.)
Srihari V, Li F. DUP redux: Observations vs. experiments in early intervention (invited commentary on Nkire et al.). Schizophrenia Research 2022, 251: 46-48. PMID: 36565532, DOI: 10.1016/j.schres.2022.12.006.Peer-Reviewed Original ResearchReal‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity
Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.Peer-Reviewed Original ResearchConceptsPediatric weight management interventionsHealthy lifestyle interventionReal-world effectivenessWeight management interventionsLifestyle interventionChildhood obesityClinical effectivenessFemale sexInsurance categoriesBMIp95Mixed-effects modelsGreater reductionBMIBright bodiesInterventionSexParticipantsManagement interventionsObesityReal-world adaptationYearsTrialsRacial and Ethnic Differences in Internal Medicine Residency Assessments
Boatright D, Anderson N, Kim J, Holmboe E, McDade W, Fancher T, Gross C, Chaudhry S, Nguyen M, Tiako M, Colson E, Xu Y, Li F, Dziura J, Saha S. Racial and Ethnic Differences in Internal Medicine Residency Assessments. JAMA Network Open 2022, 5: e2247649. PMID: 36580337, PMCID: PMC9857126, DOI: 10.1001/jamanetworkopen.2022.47649.Peer-Reviewed Original ResearchThe impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersImpact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistance